All Relations between Schizophrenia and Aripiprazole

Publication Sentence Publish Date Extraction Date Species
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni, Jeffrey M Cochra. Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach. ClinicoEconomics and outcomes research : CEOR. vol 15. 2023-05-30. PMID:37252199. cost-effectiveness of aripiprazole tablets with sensor versus oral atypical antipsychotics for the treatment of schizophrenia using a patient-level microsimulation modeling approach. 2023-05-30 2023-08-14 Not clear
Tianhang Zhou, Chengcheng Pu, Zetao Huang, Tianqi Gao, Enpeng Zhou, Yue Zheng, Dan Zhang, Bingjie Huang, Zhang Cheng, Chuan Shi, Xin Y. Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian journal of psychiatry. vol 84. 2023-04-24. PMID:37094459. weight changes following treatment with aripiprazole, risperidone and olanzapine: a 12-month study of first-episode schizophrenia patients in china. 2023-04-24 2023-08-14 Not clear
Tianhang Zhou, Chengcheng Pu, Zetao Huang, Tianqi Gao, Enpeng Zhou, Yue Zheng, Dan Zhang, Bingjie Huang, Zhang Cheng, Chuan Shi, Xin Y. Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian journal of psychiatry. vol 84. 2023-04-24. PMID:37094459. this study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (fes) patients and make a comparison of aripiprazole, risperidone and olanzapine. 2023-04-24 2023-08-14 Not clear
Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnse. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro). Journal of clinical psychopharmacology. 2023-04-21. PMID:37083542. consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the calgary depression scale for schizophrenia sum score in patients within the schizophrenia spectrum. 2023-04-21 2023-08-14 Not clear
Małgorzata Janas-Kozik, Dominika Dudek, Janusz Heitzman, Barbara Remberk, Jerzy Samochowiec, Agnieszka Słopień, Adam Wichnia. Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia. Psychiatria polska. vol 56. issue 4. 2023-04-19. PMID:37074823. second-generation antipsychotic agents approved for the treatment of early-onset schizophrenia - aripiprazole, lurasidone and paliperidone - enable its effective and safe treatment. 2023-04-19 2023-08-14 Not clear
Qian Li, Yun'Ai Su, Xuemei Liao, Maosheng Fang, Jianliang Gao, Jia Xu, Mingjun Duan, Haiying Yu, Yang Yang, Zhiyu Chen, Jintong Liu, Shaoxiao Yan, Peifen Yao, Shuying Li, Changhong Wang, Bin Wu, Congpei Zhang, Tianmei S. Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China. Chinese medical journal. 2023-04-04. PMID:37014776. aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in china. 2023-04-04 2023-08-14 Not clear
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocc. Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines. vol 11. issue 3. 2023-03-29. PMID:36979900. serotonin-dopamine activity modulators (sdams), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce ns. 2023-03-29 2023-08-14 Not clear
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. a randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar i disorder. 2023-03-24 2023-08-14 Not clear
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu 960) is a new long-acting injectable antipsychotic formulation for gluteal administration every 2 months, currently being investigated for the treatment of schizophrenia and bipolar i disorder (bp-i). 2023-03-24 2023-08-14 Not clear
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. the objectives of this trial were to evaluate the safety and tolerability of ari 2mrtu 960, and the similarity of aripiprazole plasma concentrations following administration of ari 2mrtu 960 or aripiprazole once-monthly 400 mg (aom 400), in adults with schizophrenia or bp-i. 2023-03-24 2023-08-14 Not clear
Daniel Schöttle, Wolfgang Janetzky, Francois Therrien, Klaus Wiedeman. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study). BMC psychiatry. vol 23. issue 1. 2023-03-15. PMID:36918846. bprs domains, items and subgroups analyses, and cgi-i ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (react study). 2023-03-15 2023-08-14 Not clear
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kan. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric disease and treatment. vol 19. 2023-03-14. PMID:36915909. aripiprazole lauroxil and paliperidone palmitate three-monthly (pp3m) lais have longer dosing intervals of 2-3 months and provide improved outcomes in patients with schizophrenia. 2023-03-14 2023-08-14 Not clear
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. 2023-03-03 2023-08-14 Not clear
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. among them, oral aripiprazole has been linked to dysfunction of the ans in schizophrenia. 2023-03-03 2023-08-14 Not clear
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. in this study, we compared ans activity between oral aripiprazole and aripiprazole once-monthly (aom) in schizophrenia. 2023-03-03 2023-08-14 Not clear
Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. the effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from us claims data. 2023-02-13 2023-08-14 Not clear
Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. to evaluate the impact of timing of aripiprazole once-monthly (aom) initiation on healthcare resource utilization (hcru), risk of hospitalization, and healthcare costs in patients with schizophrenia. 2023-02-13 2023-08-14 Not clear
Chittaranjan Andrad. Prolactin-Raising and Prolactin-Sparing Antipsychotic Drugs and the Risk of Fracture and Fragility Fracture in Patients With Schizophrenia, Dementia, and Other Disorders. The Journal of clinical psychiatry. vol 84. issue 1. 2023-02-01. PMID:36724110. an observational study that controlled for confounding by indication and illness severity found that fragility fractures in patients with schizophrenia were associated with higher daily doses, higher cumulative doses, longer duration of treatment, and prolactin-raising rather than prolactin-sparing antipsychotics; in patients receiving prolactin-raising antipsychotics, the concurrent use of aripiprazole appeared protective. 2023-02-01 2023-08-14 Not clear
Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research. vol 252. 2023-01-27. PMID:36706475. to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. 2023-01-27 2023-08-14 Not clear
Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 1. 2023-01-26. PMID:36700312. effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. 2023-01-26 2023-08-14 Not clear